Frontiers in immunology · 2026
Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab-axitinib and subsequent nephrectomy: a Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Polito Mariam Grazia, Caruso Davide, Cosimati Antonella, Ramirez Reinaga Carla Adriana, Leka Etien, Fuschi Andrea, Pastore Antonio Luigi, Carbone Antonio, Lako Kostika, Di Cristofano Claudio, Petrozza Vincenzo, Santini Daniele, Spinelli Gian Paolo
Аннотация
BACKGROUND: Renal cell carcinoma (RCC) is the most common kidney cancer in adults. The advent of immune checkpoint inhibitors (ICIs), particularly in combination with tyrosine kinase inhibitors (TKIs), has significantly improved outcomes in advanced disease.
CASE PRESENTATION: A 67-year-old woman with stage IV clear cell RCC and intermediate-risk features presented with pulmonary, nodal, and peritoneal metastases. She received first-line pembrolizumab plus axitinib, achieving durable disease control and partial response with good tolerability. After 32 months she achieved sustained disease stability and underwent robot-assisted left nephrectomy. Histology revealed complete pathological response. Postoperatively, pembrolizumab was continued with a pseudo-adjuvant intent, and as of March 2026, the patient remains in radiological near-complete response with a progression-free survival of approximately 41 months from treatment initiation.
DISCUSSION AND CONCLUSIONS: This case illustrates that ICI-TKI combinations can induce profound and durable responses even in intermediate-risk metastatic RCC. Consolidative surgery after systemic control, though still under debate, may be beneficial for carefully selected patients. Overall, this report underscores the potential of immunotherapy-TKI combinations to achieve long-term remission and the importance of a multidisciplinary, personalized treatment approach in advanced RCC.
CASE PRESENTATION: A 67-year-old woman with stage IV clear cell RCC and intermediate-risk features presented with pulmonary, nodal, and peritoneal metastases. She received first-line pembrolizumab plus axitinib, achieving durable disease control and partial response with good tolerability. After 32 months she achieved sustained disease stability and underwent robot-assisted left nephrectomy. Histology revealed complete pathological response. Postoperatively, pembrolizumab was continued with a pseudo-adjuvant intent, and as of March 2026, the patient remains in radiological near-complete response with a progression-free survival of approximately 41 months from treatment initiation.
DISCUSSION AND CONCLUSIONS: This case illustrates that ICI-TKI combinations can induce profound and durable responses even in intermediate-risk metastatic RCC. Consolidative surgery after systemic control, though still under debate, may be beneficial for carefully selected patients. Overall, this report underscores the potential of immunotherapy-TKI combinations to achieve long-term remission and the importance of a multidisciplinary, personalized treatment approach in advanced RCC.